Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
J Autoimmun ; 141: 103033, 2023 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-37085337

RESUMO

AIMS: Clostridioides difficile infection (CDI) is a major challenge for healthcare systems. Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease, is a risk factor for primary and recurrent CDI (rCDI). Moreover, CDI itself often worsens the clinical picture of IBD, increasing the risk of complications. Fecal microbiota transplantation (FMT) is a highly effective treatment for rCDI, but data from patients with IBD and CDI are limited and often referred to mixed cohorts. We aimed to report outcomes from a cohort of patients with UC treated with FMT for rCDI superinfection. METHODS AND RESULTS: In a retrospective, single-centre cohort study we evaluated characteristics and outcomes of patients with UC who received FMT for rCDI. The primary outcome was negative C. difficile toxin 8 weeks after FMT. Thirty-five patients were included in the analysis. Sixteen patients were cured after single FMT, while 19 patients received repeat FMT. Overall, FMT cured rCDI in 32 patients (91%), and repeat FMT was significantly associated with sustained cure of CDI compared with single FMT (84% vs 50%, p = 0.018). Twenty-four patients (69%) experienced remission or an amelioration of UC activity. Serious adverse events were not observed. CONCLUSIONS: In our cohort of patients with UC, FMT was highly effective in curing rCDI without severe adverse events and repeat FMT was significantly associated with CDI cure. Most patients also experienced remission or amelioration of UC activity after FMT. Our findings suggest that a sequential FMT protocol may be used routinely in patients with UC and rCDI.


Assuntos
Clostridioides difficile , Infecções por Clostridium , Colite Ulcerativa , Doenças Inflamatórias Intestinais , Humanos , Transplante de Microbiota Fecal/efeitos adversos , Colite Ulcerativa/terapia , Estudos Retrospectivos , Estudos de Coortes , Recidiva , Infecções por Clostridium/complicações , Infecções por Clostridium/tratamento farmacológico , Doenças Inflamatórias Intestinais/etiologia , Resultado do Tratamento
2.
Microbes Infect ; 26(5-6): 105341, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-38679228

RESUMO

Fecal microbiota transplantation (FMT) is effective against recurrent Clostridioides difficile infection (rCDI), but its safety is jeopardized by the potential transmission of pathogens, so international guidelines recommend either a quarantine or a direct stool testing. Whereas reports of the quarantine-based approach are emerging, data on the direct testing-based approach are not available. Our aim is to report outcomes of a donor screening framework for FMT including direct stool testing. In this prospective cohort study, all donor candidates recruited at our FMT centre underwent a four-step screening process to be enrolled as actual donors. Each collected stool donation was then evaluated with a direct stool testing including a molecular assay for gut pathogens and a culture assay for multi-drug resistant organisms (MDRO). From January 2019 to June 2023, 72 of 227 candidates (32%) were considered eligible and provided 277 stool donations. Ninety-nine donations (36%) were discarded for positivity to intestinal pathogens, most commonly enteropathogenic Escherichia coli (n = 37) and Blastocystis hominis (n = 20). Overall, 337 stool aliquots were obtained from 165 approved donations. All suspensions were used for patients with rCDI, and no serious adverse events or clinically evident infections were observed at 12 weeks after procedures. In our study, screening of donor faeces including direct stool testing led to the discard of a considerable rate of stool donations but was also extremely safe. This approach may represent a reliable strategy to guarantee the safety of FMT programs, especially in countries with high prevalence of MDRO.


Assuntos
Infecções por Clostridium , Seleção do Doador , Transplante de Microbiota Fecal , Fezes , Humanos , Transplante de Microbiota Fecal/métodos , Estudos Prospectivos , Fezes/microbiologia , Fezes/parasitologia , Feminino , Masculino , Pessoa de Meia-Idade , Infecções por Clostridium/diagnóstico , Infecções por Clostridium/terapia , Infecções por Clostridium/microbiologia , Seleção do Doador/métodos , Idoso , Adulto , Clostridioides difficile/isolamento & purificação , Microbioma Gastrointestinal
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa